Metra Biosystems invests in Cholestech:
This article was originally published in Clinica
Metra Biosystems will develop and market a cassette for Cholestech's LDX system to assess bone resorption. Metra, which has also made a "small equity investment" in Cholestech, will use its Pyrilinks-D urine assay for the new cassette. Additional equity investments will be made on completion of development milestones. Cholestech will market the assay in the US and both companies will distribute it internationally. The agreement between the two companies also provides for additional Metra assays to be added to the Cholestech system.
You may also be interested in...
Can shaving ever be “friction free”? Not according to Procter & Gamble, which challenged in a complaint to the UK Advertising Standards Authority a claim made by a British cosmetics firm FFS that it provided a “friction free” shaving experience for women via its subscription razor service.
Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.